|
Biogen Idec presenterà i nuovi dati relativi al suo portafoglio di prodotti …
ANSA.it Il processo ad alto rendimento Daclizumab (DAC HYP) è una formulazione sottocutanea di daclizumab nelle fasi finali dello sviluppo clinico per il trattamento della SM recidivante-remittente (RRMS), la forma più comune di sclerosi multipla. Il DAC HYP è … |
 WKYC-TV |
Hits to head may spur brain-damaging immune response
Fox News Because the body is not used to seeing this protein in the blood, it may develop antibodies to it. The body produces antibodies to fight what it perceives to be a harmful substance. If these antibodies then find their way back into the brain, they … Football Concussions May Trigger MS-Like Response in the BrainEveryday Health Head injuries may spark immune system attackFuturity: Research News Study indicates brain injuries among college football playersUSA TODAY KVEO-TV –U.S. News & World Report –SI.com all 16 news articles » |
|
Biogen Idec presenta nuevos datos sobre sus diversas carteras neurológicas …
Lainformacion.com La empresa también presentarán resultados de ensayos en fase de investigación de su cartera de productos EM de fase avanzada, incluidos TECFIDERA (dimetilfumarato), peginterferón beta-1a y el proceso de alto rendimiento daclizumab (DAC HYP). |
|
Biogen Idec presenta nuevos datos sobre sus diversas carteras neurológicas …
ecodiario La empresa también presentarán resultados de ensayos en fase de investigación de su cartera de productos EM de fase avanzada, incluidos TECFIDERA TM (dimetilfumarato), peginterferón beta-1a y el proceso de alto rendimiento daclizumab (DAC HYP). |
|
Novartis’s Biosimilar Rituxan Is ‘On Track,’ Sandoz Head Says
Bloomberg Companies including Boehringer Ingelheim GmbH are racing to bring a biosimilar version of the drug, also known as rituximab, to the market. The original compound, sold by Roche Holding AG (ROG) and Biogen Idec Inc. (BIIB), had about $7 billion in sales … |
|
– Des données sur de nouvelles options thérapeutiques renforcent la franchise …
BFMTV.COM La société publiera aussi les résultats des essais expérimentaux de sa filiale de commercialilsation de produits SEP au stade avancé, dont TECFIDERA™ (fumarate de diméthyle), l’interféron bêta-1a pégylé et le procédé à haut rendement du daclizumab … |
 Science a Gogo |
Hits to Head May Spur Brain-Damaging Immune Response
Yahoo! News (blog) Because the body is not used to seeing this protein in the blood, it may develop antibodies to it. The body produces antibodies to fight what it perceives to be a harmful substance. If these antibodies then find their way back into the brain, they … Sports brain injury may actually be an autoimmune phenomenonScience a Gogo Football Injuries May Trigger Harmful Immune System ResponseU.S. News & World Report Study: Football players can suffer brain changes without concussionsWKYC-TV Plain Dealer –KSN-TV –Popular Science all 12 news articles » |
|
Emory studies immune system reaction to rapidly mutating HIV
Atlanta Business Chronicle (blog) Some infected individuals (about 20percent-to-30 percent) develop “broadly neutralizing antibodies,” which can inactivate several varieties of HIV – not just the kind in that person, according to Emory University. These antibodies stick to parts of HIV … |
|
Roche’s Rituxan Cures Rare Skin-Blistering Disease in Study
Bloomberg “With one shot of rituximab we have a long-term result,” he said, using Rituxan’s generic name. Rituxan, approved as a treatment for lymphoma, leukemia and rheumatoid arthritis, had sales of 6.7 billion Swiss francs ($7.1 billion) last year, making it … |
|
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN …
Investor’s Business Daily The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company’s overall … |